Indications

The prevention and treatment of scurvy, or other conditions requiring vitamin C supplementation, where the deficiency is acute or oral administration is difficult.

Dosage and Administration

Dosage:

1.Adults:0.5 to 1g daily for scurvy, 200 to 500mg daily for preventative therapy. 2.Children:100 to 300mg daily for curative purposes, or 30mg daily for protective treatment.

3.Elderly No special dosage requirements have been suggested

Usage:Parenteral

Contraindications:

Hyperoxaluria

Precautions & Warning:

1.Vitamin C Injection should be given with care to patients with underlying renal failure due to the risk of formation of renal oxalate calculi.

2.Tolerance may be induced in patients taking high doses.

3.Large doses of Ascorbic Acid have resulted in haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Adverse Reactions:

1.Large doses may cause gastrointestinal disorders including diarrhoea.

2.Large doses may also result in hyperoxaluria and renal oxalate calculi may form if the urine becomes acidic. Doses of 600mg or more daily have a diuretic action.

3.Induced tolerance with prolonged use of large doses can result in symptoms of deficiency when intake is reduced to normal.

Drug interactions:

1.Drugs which induce tissue desaturation of Vitamin C Injection include aspirin, nicotine from cigarettes, alcohol, several appetite suppressants, iron, phenytoin, some anti-convulsant drugs, the oestrogen component of oral contraceptives and tetracycline.

2.Large doses of Vitamin C Injection may cause the urine to become acidic causing unexpected renal tubular reabsorption of acidic drugs, thus producing an exaggerated response. Conversely basic drugs may exhibit decreased reabsorption resulting in a decreased therapeutic effect.

3.Large doses may reduce the response to oral anticoagulants. It has been reported that concurrent administration of Vitamin C Injection and fluphenazine has resulted in decreased fluphenazine plasma concentrations. Vitamin C Injection is a strong reducing agent and interferes with numerous laboratory tests based on oxidation - reduction reactions.

4.Specialised references should be consulted for specific information on laboratory test interferences caused by Vitamin C Injection.

5.Vitamin C Injection given in addition to desferrioxamine in patients with iron overload to achieve better iron excretion may worsen iron toxicity, particularly to the heart, early on in the treatment when there is excessive tissue iron. Therefore it is recommended that in patients with normal cardiac function Vitamin C Injection should not be given for the first month after starting desferrioxamine.

6.Vitamin C Injection should not be given in conjunction with desferrioxamine in patients with cardiac dysfunction.

7.Aspirin can reduce the absorption of Vitamin C Injection by approximately a third and decreases urinary excretion by about half.

8. The clinical importance of this is uncertain. Patients with kidney failure given aluminium antacids and oral citrate can develop a potentially fatal encephalopathy due to marked rise in blood aluminium levels.

9.There is evidence that vitamin C may interact similarly.

10.Oral contraceptives lower serum levels of Vitamin C.

Storage instructions:

Store below 30℃。